CO6290675A2 - Derivados de 19-nor-esteroide que tiene un grupo 15 alfa, 16 alfa-metileno y un anillo de 17 , 17 -e espirolactona saturado su uso y medicamentos que los comprenden - Google Patents

Derivados de 19-nor-esteroide que tiene un grupo 15 alfa, 16 alfa-metileno y un anillo de 17 , 17 -e espirolactona saturado su uso y medicamentos que los comprenden

Info

Publication number
CO6290675A2
CO6290675A2 CO10078685A CO10078685A CO6290675A2 CO 6290675 A2 CO6290675 A2 CO 6290675A2 CO 10078685 A CO10078685 A CO 10078685A CO 10078685 A CO10078685 A CO 10078685A CO 6290675 A2 CO6290675 A2 CO 6290675A2
Authority
CO
Colombia
Prior art keywords
hydrogen
alpha
methylene
group
alkyl
Prior art date
Application number
CO10078685A
Other languages
English (en)
Inventor
Ulrich Klar
Joachim Kuhnke
Katja Prelle
Hans-Peter Muhn
Steffen Borden
Frederik Menges
Thomas Frenzel
Sven Ring
Jan Hubner
Rolf Bohlmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40548690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290675(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6290675A2 publication Critical patent/CO6290675A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los derivados de ?-lactona del ácido 15a, 16a-metilen-17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxílico de la presente invención poseen efectividad gestagénica.Tienen la fórmula química general I, en la cual Z se selecciona del grupo que comprende un átomo de oxígeno, dos átomos de hidrógeno, NOR y NNHSO2R, donde R es hidrógeno, alquilo-C1-C10, arilo o aralquilo-C7-C20, R4 es hidrógeno o halógeno; además, R6a, R6b forman juntos metileno o 1,2-etandiilo o R6a es hidrógeno y R6b se selecciona del grupo que comprende hidrógeno, alquilo-C1-C10, alquenilo-C2-C10 o alquinilo-C2-C10, y R7 se selecciona del grupo que comprende hidrógeno, alquilo-C1-C10, cicloalquilo-C3-C6, alquenilo-C2-C10 o alquinilo-C2-C10, o: R6a es hidrógeno y R6b y R7 juntos forman un enlace, un oxígeno o metileno, R18 representa hidrógeno o alquilo-C1-C3 y comprenden además sus solvatos, hidratos, estereoisómeros y sales.
CO10078685A 2007-12-29 2010-06-29 Derivados de 19-nor-esteroide que tiene un grupo 15 alfa, 16 alfa-metileno y un anillo de 17 , 17 -e espirolactona saturado su uso y medicamentos que los comprenden CO6290675A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063495A DE102007063495A1 (de) 2007-12-29 2007-12-29 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
CO6290675A2 true CO6290675A2 (es) 2011-06-20

Family

ID=40548690

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10078685A CO6290675A2 (es) 2007-12-29 2010-06-29 Derivados de 19-nor-esteroide que tiene un grupo 15 alfa, 16 alfa-metileno y un anillo de 17 , 17 -e espirolactona saturado su uso y medicamentos que los comprenden

Country Status (26)

Country Link
US (2) US20100311702A1 (es)
EP (1) EP2238149B1 (es)
JP (1) JP5600071B2 (es)
KR (1) KR20100102136A (es)
CN (1) CN101910192B (es)
AR (1) AR069962A1 (es)
AU (1) AU2008342916A1 (es)
BR (1) BRPI0821666A2 (es)
CA (1) CA2710495C (es)
CL (1) CL2008003919A1 (es)
CO (1) CO6290675A2 (es)
DE (1) DE102007063495A1 (es)
DO (1) DOP2010000199A (es)
EA (1) EA201000982A1 (es)
EC (1) ECSP10010315A (es)
ES (1) ES2539121T3 (es)
HK (1) HK1151532A1 (es)
IL (1) IL206019A0 (es)
NZ (1) NZ586453A (es)
PA (1) PA8810701A1 (es)
PE (1) PE20091336A1 (es)
TW (1) TW200940074A (es)
UA (1) UA98834C2 (es)
UY (1) UY31580A1 (es)
WO (1) WO2009083272A2 (es)
ZA (1) ZA201005395B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334375B2 (en) * 2009-04-10 2012-12-18 Evestra, Inc. Methods for the preparation of drospirenone
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
EP2265629B1 (en) * 2008-03-05 2015-06-24 Evestra, Inc. Bismethylene-17 carbolactones and related uses

Also Published As

Publication number Publication date
PE20091336A1 (es) 2009-10-04
EP2238149B1 (de) 2015-03-18
CA2710495A1 (en) 2009-07-09
IL206019A0 (en) 2010-11-30
BRPI0821666A2 (pt) 2015-06-16
DE102007063495A1 (de) 2009-09-17
WO2009083272A3 (de) 2009-08-27
AU2008342916A1 (en) 2009-07-09
KR20100102136A (ko) 2010-09-20
HK1151532A1 (es) 2012-02-03
WO2009083272A2 (de) 2009-07-09
CA2710495C (en) 2015-04-28
EA201000982A1 (ru) 2011-02-28
EP2238149A2 (de) 2010-10-13
AR069962A1 (es) 2010-03-03
CN101910192B (zh) 2013-07-31
US20100311702A1 (en) 2010-12-09
DOP2010000199A (es) 2010-10-15
US20130123219A1 (en) 2013-05-16
ECSP10010315A (es) 2010-08-31
JP5600071B2 (ja) 2014-10-01
NZ586453A (en) 2012-05-25
UY31580A1 (es) 2009-08-03
TW200940074A (en) 2009-10-01
JP2011507928A (ja) 2011-03-10
ES2539121T3 (es) 2015-06-26
UA98834C2 (ru) 2012-06-25
CL2008003919A1 (es) 2010-05-07
ZA201005395B (en) 2012-01-25
PA8810701A1 (es) 2009-12-16
CN101910192A (zh) 2010-12-08
US8987239B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
AR107519A1 (es) Compuestos de piperidina sustituido y su uso
AR066970A1 (es) Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene
AR123441A2 (es) Compuesto de pirazol
AR069334A1 (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana
ES2592713T3 (es) Derivados de indazolil-triazol como inhibidores de IRAK
AR067823A1 (es) Compuestos de amina ciclica
PA8813101A1 (es) Derivados bicílicos de carboxamidas aza-bicíclicas,su preparación y su aplicación terapéutica
ECSP11010946A (es) Nuevos compuestos heterocíclicos nitrogenados, preparación de los mismos y utilización de los mismos como medicamentos antibacterianos
ECSP099216A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6321168A2 (es) Nuevos derivados de 2-amidotiadiazol
AR090112A1 (es) Sulfinilaminobenzamidas efectivas como herbicidas
CY1124908T1 (el) Παραγωγο μορφινανης
AR102731A1 (es) Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor
AR076252A1 (es) Inhibidores de la replicacion del vih
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO6290675A2 (es) Derivados de 19-nor-esteroide que tiene un grupo 15 alfa, 16 alfa-metileno y un anillo de 17 , 17 -e espirolactona saturado su uso y medicamentos que los comprenden
AR109467A1 (es) Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño
CO6251285A2 (es) Derivado de tetrahidroisoquinolina novedoso
AR115020A1 (es) Compuesto heterocíclico nitrogenado y su uso como antagonista del receptor nmda
AR066971A1 (es) Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contiene
ATE528284T1 (de) Metallcarbamate aus tolylendiaminen
PA8856201A1 (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicacion en terapeutica como activadores de hif"
CO2018007788A2 (es) Compuesto novedoso de ácido bisfosfónico
CU20100137A7 (es) Derivados de 19-nor-esteroide que tiene un grupo 15, 16-metileno y un anillo de 17, 17-espirolactona saturado, su uso y medicamentos que los comprenden
CY1114378T1 (el) Μεθοδος χρησιμοποιησης συνδυασμου παραγωγου βενζοφαινονης ή αλατος αυτου και ανοσοκατασταλτικου παραγοντα, και φαρμακευτικη συνθεση που περιλαμβανει αυτα τα συστατικα

Legal Events

Date Code Title Description
FC Application refused